Northwest Bank & Trust Co acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,420 shares of the company’s stock, valued at approximately $235,000.
Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Atlantic Private Wealth LLC bought a new stake in Johnson & Johnson during the 1st quarter valued at $32,000. Dark Forest Capital Management LP grew its stake in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $42,000. Kepos Capital LP purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $45,000. Finally, 25 LLC purchased a new position in Johnson & Johnson in the 1st quarter valued at $55,000. Institutional investors own 68.40% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on JNJ shares. HSBC assumed coverage on Johnson & Johnson in a report on Wednesday, September 6th. They set a “hold” rating and a $175.00 price target on the stock. Morgan Stanley lowered their price objective on Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating for the company in a research report on Thursday, August 31st. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, September 18th. Finally, Credit Suisse Group upped their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Nine investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $170.65.
Insider Buying and Selling at Johnson & Johnson
In other news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
Johnson & Johnson Trading Down 0.7 %
NYSE:JNJ opened at $155.75 on Monday. The company has a market cap of $404.79 billion, a PE ratio of 31.53, a P/E/G ratio of 3.15 and a beta of 0.55. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $165.97 and its two-hundred day moving average is $162.29.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business’s revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the business posted $2.59 EPS. On average, analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.06%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Want to Profit on the Downtrend? Downtrends, Explained.
- Will the Energy Sector Continue to Outshine the Market?
- Investing In Automotive Stocks
- MarketBeat Week in Review – 9/25 – 9/29
- How Technical Indicators Can Help You Find Oversold Stocks
- CarMax Slides On Earnings Disappointment, Time To Celebrate?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
